Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

The Lancet Oncology

Volumn 19, Issue 2, 2018, Pages 240-248

  Kantarjian, Hagop ^a   Ravandi, Farhad ^a   Short, Nicholas J ^a   Huang, Xuelin ^a   Jain, Nitin ^a   Sasaki, Koji ^a   Daver, Naval ^a   Pemmaraju, Naveen ^a   Khoury, Joseph D ^a   Jorgensen, Jeffrey ^a   Alvarado, Yesid ^a   Konopleva, Marina ^a   Garcia Manero, Guillermo ^a   Kadia, Tapan ^a   Yilmaz, Musa ^a   Bortakhur, Gautam ^a   Burger, Jan ^a   Kornblau, Steven ^a   Wierda, William ^a   DiNardo, Courtney ^a   Ferrajoli, Alessandra ^a   Jacob, Jovitta ^a   Garris, Rebecca ^a   O'Brien, Susan ^b   Jabbour, Elias ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; INOTUZUMAB OZOGAMICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLERGIC REACTION; ANOREXIA; ARTICLE; ASCITES; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOCALCEMIA; HYPOFIBRINOGENEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; INFECTION; INSOMNIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; THROMBOCYTOPENIA; UNITED STATES; VEIN OCCLUSION; VOMITING; WEAKNESS; CANCER CENTER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; GERIATRIC ASSESSMENT; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PATIENT SAFETY; PATIENT SELECTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TEXAS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERIATRIC ASSESSMENT; HUMANS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SAFETY; PATIENT SELECTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TEXAS; TREATMENT OUTCOME; VINCRISTINE;

EID: 85041121752     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30011-1     Document Type: Article

References (29)

1. Jabbour, E, O'Brien, S, Konopleva, M, Kantarjian, H, New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121 (2015), 2517–2528.
2. Hoelzer, D, Walewski, J, Dohner, H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood 124 (2014), 3870–3879.
3. Thomas, DA, Faderl, S, O'Brien, S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106 (2006), 1569–1580.
4. Ribrag, V, Koscielny, S, Bosq, J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 387 (2016), 2402–2411.
5. Thomas, DA, O'Brien, S, Faderl, S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28 (2010), 3880–3889.
6. Maury, S, Chevret, S, Thomas, X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 375 (2016), 1044–1053.
7. Fielding, AK, Rowe, JM, Buck, G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123 (2014), 843–850.
8. Ravandi, F, O'Brien, S, Thomas, D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116 (2010), 2070–2077.
9. Jabbour, E, Kantarjian, H, Ravandi, F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16 (2015), 1547–1555.
10. Jain, P, Kantarjian, H, Ravandi, F, et al. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia 28 (2014), 973–975.
11. Gokbuget, N, How I treat older patients with ALL. Blood 122 (2013), 1366–1375.
12. O'Brien, S, Thomas, DA, Ravandi, F, Faderl, S, Pierce, S, Kantarjian, H, Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer 113 (2008), 2097–2101.
13. Goekbuget, N, Beck, J, Brueggemann, M, et al. Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a prospective trial from the German multicenter study group for adult ALL (GMALL). Blood, 120, 2012, 1493 (abstr).
14. Li, S, Molony, JT, Chia, V, Katz, AJ, Patient characteristics and treatment patterns in elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) using 100% Medicare ALL data. Blood, 128, 2016, 3981 (abstr).
15. Geyer, MB, Hsu, M, Devlin, SM, Tallman, MS, Douer, D, Park, JH, Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood 129 (2017), 1878–1881.
16. Thomas, X, Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs 21 (2012), 871–878.
17. Kantarjian, H, Thomas, D, Jorgensen, J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119 (2013), 2728–2736.
18. Kantarjian, H, Thomas, D, Jorgensen, J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13 (2012), 403–411.
19. Kantarjian, HM, DeAngelo, DJ, Stelljes, M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375 (2016), 740–753.
20. Kantarjian, HM, O'Brien, S, Smith, TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 18 (2000), 547–561.
21. Kantarjian, H, Thomas, D, O'Brien, S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101 (2004), 2788–2801.
22. Mohty, M, Malard, F, Abecassis, M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 51 (2016), 906–912.
23. Ravandi, F, Jorgensen, JL, O'Brien, SM, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172 (2016), 392–400.
24. Jabbour, E, Short, NJ, Jorgensen, JL, et al. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123 (2017), 294–302.
25. Jabbour, E, O'Brien, S, Ravandi, F, Kantarjian, H, Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125 (2015), 4010–4016.
26. Jabbour, E, Ravandi, F, Kebriaei, P, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol, 2017 published online Aug 31. DOI:10.1001/jamaoncol.2017.2380.
27. Kantarjian, HM, DeAngelo, DJ, Advani, AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol 4 (2017), e387–e398.
28. Kantarjian, H, Stein, A, Gokbuget, N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376 (2017), 836–847.
29. Kantarjian, HM, Stein, AS, Bargou, RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies. Cancer 122 (2016), 2178–2185.